Conférences  >  Médecine & Soins de Santé  >  Pharmacologie et développement des médicaments

Formation professionnelle continue en chimie,    Génie chimique

Uventia Global

The formation of nitrosamines as well as other mutagenic impurities in drug substances and drug products may compromise their safety, quality, and clinical outcomes. Estimating impurity profiles, as well as controlling and monitoring them, has become an unavoidable aspect of the comprehensive development and production of novel medicines. The proactive detection of genotoxic impurities should be implemented at every step of drug development to comply with growing regulatory standards and avoid costly recalls.

Tél.: [7328234626];     Email.: info@uventia.com

nitrosamine impurity risk assessment to optimize timeframes and costs, reducing nitrosamine contamination from raw materials to finished drugs, appropriate analytical instruments for detecting nitrosamine impurities, practical and compliant implementation of ICH M7 and ICH Q3D guidance, impurity profiling in drug substances, intermediates, and drug products, E&L as an impurity source – removing the risks associated with E&L

IMPACT Conferences

We are glad to welcome all the participants to the "5th international conference on Pharmaceutics and Drug Delivery Research," (Virtual pharma 2022) scheduled for December 02-04, 2022. It mainly focuses on the theme “Innovative Approaches in Pharmaceutical Science and Drug Delivery systems". The conference will bring together academics, researchers, scientists, scholars, and professors, pharmacists, drug delivery specialists, nanotechnologists, clinicians, chemists, healthcare professionals, business representatives, and delegates from a wide range of disciplines to discuss the most recent findings and trends in pharmaceutics and drug delivery research. This three-day event includes keynote talks, oral presentations, poster sessions by young researchers and students, seminars, and networking opportunities.

Email.: pharmawebconference@gmail.com

• Advanced Drug Delivery Systems • Cellular Targeting and Intracellular Delivery • Pharmacogenomics • Drug Delivery Through BBB • Pharmacovigilance and Drug Safety • Pharmaceutical Research & Development • Novel Drug Delivery Systems, Biomarkers & Drug Targets • Nanotechnology in Pharmaceutics and Drug Delivery Systems • Pharmaceutical/Medicinal Chemistry • Pharmaceutical Microbiology & Biotechnology • Pharmacy Practice, Clinical and Hospital Pharmacy • Pharmaceutical Product Development and Manufacturing • Inhaled Drug Delivery • Research On Oncology And AIDS • Bio-Drugs, Bio-Molecules and Therapeutics • Biotherapy and Radiopharmaceuticals • Therapeutic Drug Carrier Systems • Drug Discovery and Screening • Anticancer drug delivery for Tumor Targeting • Preformulation Studies • Formulation Technologies • Vaccine Design and Drug Delivery Technology • Peptides and Protein Drug Delivery • Clinical And Medical Case Reports • Drug Discovery and Development • Pharmacognosy and Phytochemistry • Pharmacokinetics, Pharmacodynamics • Pharmacology & Toxicology • Nutraceuticals • Virtual Healthcare and Pharmaceuticals • Precision Medicine and Specialty Drugs • Cosmeceuticals • Biosimilars Market • Pharmaceutics Business and Market • Artificial Intelligence in Pharma • Regulatory Affairs and Quality Assurance

Cambridge Healthtech Institute

There have been tremendous advancements and breakthroughs in cell therapy treatments. Autologous treatments are extremely effective personalized therapies, but have significant medical, cost and commercialization limitations. Allogeneic treatments provide us with an opportunity to expand and extend access to personalized therapies to patients in need, but face efficacy, safety, and process hurdles. While related, the differences are stark, forcing your company to make unique and critical process and business decisions to ensure your company implements the best technologies to execute the most effective autologous and/or allogeneic cell therapy manufacturing strategy.

Tél.: [7812476254];     Email.: ebell@healthtech.com

cell.cell therapy, gene therapy, biotech, bioprocess, bioprocessing, chi, virtual, remo, allogenic, autologous

SAE Media Group

The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to increase patient centricity, aid self-administration and deliver biologics that have large-volumes and novel formulations. This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma, device developers and regulators can work together to encourage innovation.

Tél.: [+44 (0) 20 7827 6086];     Email.: rjones@smi-online.co.uk

Pre-Filled Syringes, Injectable Drug Devices, drug development, regulatory guidelines, pharmaceutical industry, drug delivery, therapeutic sectors, vaccines, Parenteral administration, combination products, primary packaging, sterile injectables, connectivity, human factors, autoinjectors

SAE Media Group

Harnessing Alternative Rapid Microbial Methods for a Successful Contamination Control Strategy

Microbiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. This conference will explore the most pressing topics in this thriving field, from the movement toward process automation and increased regulatory stringency, to the latest technologies in rapid microbiological testing methods and data integrity.

Tél.: [02078276162];     Email.: ssapal@smi-online.co.uk

Pharmaceutical, microbiology, contamination control, microbial, biofilms, sterility, quality assurance, mycoplasma, data integrity, microbiome, Endotoxin, Alternative Rapid Microbiological Methods

Pharmacogénétique, Médecine personnalisée,    Immunologie et Allergie

Scientific Update Ltd.

This three-day course, written and presented by highly experienced process chemists from the pharmaceutical and fine chemical industry, provides a comprehensive overview of this fascinating and important element of the chemical industry. A logical investigative approach to all aspects of chemical development is described, with an abundance of case studies from literature, conferences and private communications. The multi-disciplinary nature of chemical development is emphasised, from the initial interaction with laboratory research scientists to the vital partnership with chemical engineers in the pilot plant and in the production environment. The lectures are interspersed with interactive problem sessions, enabling participants to share in the problem solving and troubleshooting typically experienced during chemical development.

Formation professionnelle continue en chimie,    Génie chimique

Hanson Wade

The inaugural Next Generation Ophthalmic Drug Delivery Summit is coming to San Francisco in January 2023, to help ophthalmic drug developers overcome translational challenges of developing novel long-lasting ophthalmic therapies via novel delivery methods to reduce healthcare burden and increase patient compliance. Join 21+ expert speakers from the likes of Genentech, Aerie Pharmaceuticals, Novartis, Clearside Biomedical, Janssen, Eyevensys, and EyePoint Pharmaceuticals to overcome your translational challenges and enhance extended drug efficacy while avoiding systemic and local adverse effects. Don’t miss your only opportunity for an industry-specific meeting for networking and sharing extended-duration therapies with the ophthalmic drug development community.

Hanson Wade;     Tél.: [(+1) 617 455 4188];     Email.: info@hansonwade.com

Ophthalmic, Drug Delivery, Ocular, ophthalmic therapies, eye, pharmaceuticals, Gene Therapy

Adichunchanagiri College of Pharmacy & Association of Pharmaceutical Research

Pharma Conference 2022 focuses on the medical break throughs; this Upcoming Pharmaceutical Science Conference is to rectify issues and provide solutions.

Tél.: [9342924780];     Email.: pharmasummit@apr.in.net

Pharma Conference 2022, International Pharmaceutical Conference, Pharmaceutical Conference, Upcoming Pharmaceutical Conference, Pharma Conference, Pharma Conference in 2022, Upcoming Pharma Conference, International Pharma Conference, Pharmaceutical Conference in Bangalore

Scientific Update Ltd.

5 sessions aim to give chemists and chemical engineers a thorough practical knowledge of crystallisation processes. After an introduction the course will cover crystallisation of compounds (including hydrates and solvates), different methods of crystallisation, polymorphism, salts and co-crystals, crystallisation of chiral compounds and classical resolution, analytical methods for studying the solid state and will finish with some case studies. Real life practical examples will be used throughout the course to exemplify the different aspects of crystallisation and polymorphism. The course will cover all aspects of the subject including crystallization of intermediates as well as final products. In addition, precipitations and amorphous solids will be covered and the differences between amorphous solids and crystalline solids will be discussed.

Formation professionnelle continue en chimie,    Génie chimique

Scientific Update Ltd.

This three-day course, written and presented by highly experienced process chemists from the pharmaceutical and fine chemical industry, provides a comprehensive overview of this fascinating and important element of the chemical industry. A logical investigative approach to all aspects of chemical development is described, with an abundance of case studies from literature, conferences and private communications. The multi-disciplinary nature of chemical development is emphasised, from the initial interaction with laboratory research scientists to the vital partnership with chemical engineers in the pilot plant and in the production environment. The lectures are interspersed with interactive problem sessions, enabling participants to share in the problem solving and troubleshooting typically experienced during chemical development.

Formation professionnelle continue en chimie,    Génie chimique

European Society for Medical Oncology

ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading congress focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development.

ESMO Registration Office;     Tél.: [+41 (0) 91 973 19 13];     Email.: registration@esmo.org

ESMO TAT, Targeted Anticancer Therapies Congress, TAT, European Society for Medical Oncology, Antibody-based therapies, Cell therapies, DNA damage repair, Epigenetics, Immunotherapy, Kinase-targeting agents and cell signalling modulators, Molecular profiling applications, cancer, oncology, clinical trials, anticancer targets and agents, cancer drugs

Médecine translationnelle, essais cliniques,    Cancérologie

Scientific Update Ltd.

This three-day course, written and presented by highly experienced process chemists from the pharmaceutical and fine chemical industry, provides a comprehensive overview of this fascinating and important element of the chemical industry. A logical investigative approach to all aspects of chemical development is described, with an abundance of case studies from literature, conferences and private communications. The multi-disciplinary nature of chemical development is emphasised, from the initial interaction with laboratory research scientists to the vital partnership with chemical engineers in the pilot plant and in the production environment. The lectures are interspersed with interactive problem sessions, enabling participants to share in the problem solving and troubleshooting typically experienced during chemical development.

Formation professionnelle continue en chimie,    Génie chimique

SCK CEN Academy

This unique course touches upon the radiobiological, radiochemical and dosimetric aspects in the development of radiopharmaceuticals. The course is organized under the umbrella of the PRISMAP project (www.prismap.eu).

Optica

Focuses on the convergence in these rapidly evolving areas, spanning from basic biology to clinical diagnostics and therapeutic applications. This multidisciplinary topical meeting will highlight recent advances in these rapidly evolving areas with a goal of stimulating novel strategies for molecular probe development, site-specific drug delivery, monitoring treatment response and clinical translation to improve diagnosis or treatment of diseases. Areas to be covered include, but are not limited to, novel molecular probe design, applications of smart molecular probes in basic and applied research, endogenous and exogenous optical molecular biomarkers, multimodal imaging, advances in instrumentation and algorithms for optical molecular imaging, molecular and functional imaging of normal and diseased tissue, image-guided drug delivery, drug screening and monitoring therapeutic response.

Opto-électronique et technique d'affichage,    Génie biomédical

Bioprocess solutions to achieve sustainable development goals; Approaches for enabling a circular economy; Novel bioprocesses as a driver for bioeconomy; Sustainability in biopharma processes; Smart bioreactor and Downstream processing concepts

Génie chimique,    Chimie industrielle et chimie verte

The meeting will explore bacterial pathogens and pathogenesis from multiple perspectives, from cellular mechanisms to interbacterial interactions and community behavior, as well as pathogenesis in the complex milieu of the microbiota. The meeting will also highlight the pathogenic potential of the microbiome and explore microbiota-based and engineered antibacterial/therapeutic approaches.

Maladies Infectieuses,    Biologie

For many years, nucleos(t)ide analogues and nucleic acids have served as cornerstones of drug design and development efforts. The Nucleosides, Nucleotides and Oligonucleotides (NNO) Gordon Research Conference is dedicated to understanding the fundamental chemistry, biology, and technologies for the diagnosis and treatment of various diseases using nucleos(t)ides and nucleic acid analogues. In recent years nucleic acids have seen wide use in chemical biology investigations as well as in the clinic as therapeutics and diagnostics. Emerging areas like CRISPR gene editing and siRNA have been developed due to the extensive efforts of many in the NNO field. The 2023 edition will be the 21st NNO GRC and will reflect the evolution of the field and the current explosive growth of NNO based therapeutics, from its original focus on purine and pyrimidine chemistry and biology, to the much broader current scope.

Chemical Biology of Nucleosides and Nucleic Acids Towards Human Therapeutics

Biologie moléculaire,    Biochimie et chimie médicale, toxicologie